TCM
TRIB

Triumph Capital Management’s Trinity Biotech TRIB Stock Holding History

Triumph Capital Management’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$542 Hold
1,000
– – ﹤0.01% 1694
2025
Q4 		$791 Buy
+1,000
New +$983 ﹤0.01% 1599

Other funds holding TRIB

HAIM
Hunter Associates Investment Management Pittsburgh, Pennsylvania $756M AUM 19.99% 1-Year Est. Return
YAG
Yorkville Advisors Global Mountainside, New Jersey $155M AUM 58.46% 1-Year Est. Return
WN
Williams & Novak Westlake Village, California $151M AUM 27.43% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
MAWA
Moss Adams Wealth Advisors Seattle, Washington $1.37B AUM 19.97% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
BCM
Becker Capital Management Portland, Oregon $3.4B AUM 24.68% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Triumph Capital Management's TRIB Position: Q1 2026 in Review

Triumph Capital Management held its Trinity Biotech (TRIB) position steady in Q1 2026 at 1,000 shares worth $542. The position accounts for ﹤0.01% of the portfolio, ranked #1694.

Triumph Capital Management first reported a position in TRIB in Q4 2025 and has held it in 2 quarters since. The position peaked at $791 in Q4 2025. 23 funds tracked by Wall St. Rank hold TRIB as of Q1 2026.

  • Triumph Capital Management held 1,000 shares of Trinity Biotech worth $542 as of Q1 2026.
  • Triumph Capital Management left its Trinity Biotech share count unchanged in Q1 2026.
  • Trinity Biotech made up ﹤0.01% of Triumph Capital Management's portfolio in Q1 2026, its #1694 holding.
  • Triumph Capital Management first reported a position in Trinity Biotech in Q4 2025 and has held it in 2 quarters since.
  • Triumph Capital Management's Trinity Biotech position peaked at $791 in Q4 2025.
  • 23 funds tracked by Wall St. Rank held Trinity Biotech as of Q1 2026.

Based on Triumph Capital Management's 13F filing for Q1 2026, filed 13 May 2026.